与转移性宫癌的tisotumab vedotin-tftv相关的急性角膜结膜炎
Ankur A Parikh1, Jovana Hanna2, Amar P Shah1,3
1Department of Ophthalmology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
American journal of ophthalmology case reports
|January 17, 2024
概括
抗体-药物结合物tisotumab vedotin-tftv在宫癌患者中引起了长期的眼球表面疾病,导致治疗中止. 眼科医生必须对新出现的抗体-药物合物进行这些不良反应的监测.
科学领域:
- 在瘤学瘤学.
- 眼科医生 眼科 眼科
背景情况:
- 提索托马布维多丁-tftv是FDA批准的用于转移性或耐治疗的宫癌的抗体-药物结合物.
- 临床试验表明,与这种治疗相关的眼部并发症的发病率很高.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
06:15Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
1.2K
